( rved in the placebo group compared to t...)Gardasil Demonstrates Up to 100% Efficacy,Health

rved in the placebo group compared to the one case of CIN3 observed in the vaccine group. ,c)

The one case of CIN3 in the vaccine group of FUTURE II involved a woman who had an infection with Human Papillomavirus type 52 at baseline and at five follow-up visits. Type16 was detected in only one of these visits suggesting that this case could have been type 52-related. To be conservative, this case was nevertheless included in the group that received the vaccine.

CIN2/3 is the obligate precursor of cervical cancer and the clinically most relevant endpoint for the US Food and Drug Administration (FDA) and the World Health Organization (WHO) to demonstrate efficacy in the prevention of cervical cancer.

In both studies, Gardasil® was generally well tolerated. The adverse events observed were similar to what has been previously reported.

Notes to editors

High efficacy has already led to vaccination of women in the placebo groups
In light of the high efficacy shown by Gardasil® at licensure, the Data and Safety Monitoring Board of FUTURE I and II had recommended that women in the placebo group should be vaccinated with Gardasil®. The board recommended that the studies should be terminated as soon as feasible in order to provide the benefits of vaccination with Gardasil® to these women rapidly. In Europe, vaccination of women in the placebo groups of FUTURE I and II has already begun in the United Kingdom, Germany, Sweden, Norway, Denmark, Finland and Austria. In other countries, vaccination will start soon with the objective to complete vaccination before the end of the year 2007. In a similar way, vaccination of women in many other countries around the world, including the US, Australia and Canada, has begun or is anticipated to begin soon.

Protection against additional virus types through cross protection
In large phase III clinical stu
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer